BARCELONA, Spain—The gout drug allopurinol on top of usual care does not improve cardiovascular outcomes in patients over age 60 who do not have gout, the ALL-HEART trial confirms. The long-running ...

August 9, 2010 (Montreal, Quebec) — An observational study of more than 25 000 heart failure patients has shown that a history of gout and/or an acute episode of gout are associated with an increased ...

Among patients with gout, allopurinol use is associated with a lower risk for urolithiasis compared with benzbromarone. Among patients with gout, allopurinol use is associated with a lower risk for ...

Trial subgroup analyses support the use of either allopurinol or febuxostat in patients with stage 3 CKD and gout. A prespecified analysis of the STOP-GOUT trial revealed that allopurinol has similar ...

Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid Tumors PURPOSE: To tabulate data obtained over a 21-year period to ...

The European Medicines Agency (EMA) has designated allopurinol as the first orphan drug for the treatment of Marfan syndrome, a rare connective tissue disease which as no cure to date. This disease ...